NCT00435812 - Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine | Biotech Hunter

Enrollment

2,428

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

March 31, 2008

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HEPLISAV and/or Placebo

Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24

BIOLOGICAL

Engerix-B

Intramuscular (IM) injections on Week 0, Week 4, and Week 24

Trial Locations (18)

Edmonton

Surrey

Winnipeg

Mount Pearl

St. John's

Halifax

Ottawa

Sarnia

Toronto

Charlottetown

Montreal

Québec

Berlin

Hamburg

Leipzig

Magdeburg

Munich

Ulm